Latest Conference Coverage

Effects of Combination Therapies, Treatment Adverse Effects in Myasthenia Gravis: Nicholas Silvestri, MD, FAAN

The clinical professor at the University at Buffalo discussed the complexities of using combination therapies to treat myasthenia gravis, and whether adverse events play a major role in treatment decisions. [WATCH TIME: 3 minutes]

NeurologyLive® Brain Games: October 9, 2022

Advancing the Treatment Paradigm for Myasthenia Gravis and Looking Toward the Future

Nicholas Silvestri, MD, clinical professor at the University at Buffalo discussed topics related to the expansion of treatments for myasthenia gravis and the positive outlook of managing the disease.

Institutional Perspectives in Neurology, Chaired by Riley Bove, MD

Chaired by Riley Bove, MD, of the University of California, San Francisco (UCSF), the presentations also feature Emmanuelle Waubant, MD, PhD, of UCSF; William L. Conte, MD, MS, of Methodist Hospitals; and Maria K. Houtchens, MD, of Harvard Medical School. [WATCH TIME: 1 hour, 31 minutes]

Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.

Progression of New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the progression of new treatment for Duchenne muscular dystrophy and provides suggestions for moving forward with research in the field. [WATCH TIME: 5 minutes]

Recommendations for Clinical Trial Design in Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

The professor of neurology and pediatrics at University of Rochester Medical Center gives some recommendations for the improvement in clinical trial design for patients with rare diseases such as Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

NeurologyLive® Brain Games: October 2, 2022

CNM-Au8 Slows Disease Progression in ALS in RESCUE-ALS Phase 2 Trial

RESCUE-ALS trial, a phase 2 randomized controlled study, showed that ALS disease progression was significantly reduced with CNM-Au8 Treatment.

Understanding Safety, Amyloid-Related Imaging Abnormalities With Lecanemab: Sharon Cohen, MD, FRCPC

The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]

Sleep Breathing Disorders Appear Common for Patients with Duchenne Muscular Dystrophy

A questionnaire-based study from Saudi Arabia on sleep quality revealed that sleep-related disorders, such as obstructive sleep apnea, are relatively common in patients with Duchenne muscular dystrophy.

Diagnosis of Myotonic Dystrophy Demonstrates an Association With Depression

Findings from a cross-sectional survey revealed a significant association between depression and a diagnosis of myotonic dystrophy, and that symptoms impacting quality of life are more common in neuromuscular disorders.

Tollgate-Related Prognostic Factors Have Stronger Effect on ALS Progression Timing Through Disease Tollgates

A study on ALS progression suggested that tollgate-related prognostic factors have a stronger effect on the time trajectories of passing ALS tollgates in comparison with standard prognostic factors.

NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy

The professor of neurology and pediatrics at the University of Rochester Medical Center provided insight on the emerging therapies and advancements for treating patients with Duchenne muscular dystrophy.

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]

Virtual Reality Training May Improve Quality of Care in Lower Limb Spasticity With OnabotulinumtoxinA

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.

Tele-Yoga Breathing for Respiratory Function Proves Feasibility in Amyotrophic Lateral Sclerosis

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.

Vaccinated Individuals With Myasthenia Gravis With COVID-19 Infection are More at Health Risk

Adults with myasthenia gravis who contracted COVID-19 were at twice the risk of hospitalization, ICU admission, and death based on data from a recent population-based study.

Evaluating the Treatment Evolution of Myasthenia Gravis and Use of Immunosuppressants: Nicholas Silvestri, MD, FAAN

The clinical professor of neurology at the University at Buffalo provided insight on the advances in treatment options for patients with myasthenia gravis over the past few decades. [WATCH TIME: 3 minutes]

Patients Receiving Efgartigimod Respond to COVID-19 Vaccination With IgG Antibodies

In an investigation on the effect of treatment with efgartigimod on humoral immune responses to COVID-19 vaccination, the immunization resulted in antigen-specific IgG responses in most patients.

Understanding New Guidelines to Improve Management of Painful Diabetic Neuropathies

Brian Callaghan, MD, MS, associate professor at the University of Michigan, discussed his presentation at AANEM 2022 on changing the treatment paradigm for painful diabetic neuropathies.

NeurologyLive® Brain Games: September 25, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Repetitive Nerve Stimulation Exhibits Positive Association with Inpatient Diagnosis of Myasthenia Gravis

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]

Substantial Economic Burden Is Frequent in Myasthenia Gravis, Primarily Driven by Direct Costs

Among a surveyed cohort of patients with myasthenia gravis, 75% reported that their work was impacted, and 27% of respondents claimed they lost wages as a result of MG.

Eplontersin Treatment Results in Reduction in Serum Transthyretin in Amyloidosis

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

Rozanolixizumab Continues to Show Efficacy, High Responder Rates in Myasthenia Gravis

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.

CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]

Pooled Clinical Trial Data Suggests Antidrug Antibody Testing for Alglucosidase Alfa-Exposed Patients With Pompe Disease

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.

ADAPT/ADAPT+ Study Show Improvements in Myasthenia Gravis Efficacy Scales With Efgartigimod

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.